Dallas, TX -- (SBWIRE) -- 10/03/2010 -- The Cardiovascular Market Outlook to 2015 provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growing brands, key drug classes and leading players through 2015.
The cardiovascular market may be segmented into numerous subcategories, including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still exists. Among the various cardiovascular indications, dyslipidemia had the highest prevalence in 2009, with approximately 333m people affected by the condition.
The global cardiovascular market is quite dynamic and has remained a leading therapy area in the global pharmaceutical market. The seven major markets (7MM) captured a significant market share of the global cardiovascular market and also recorded a moderate Y-o-Y growth in 2009. The US continued to be a dominant market and registered a Y-o-Y increase in 2009, mainly attributed to the performance of key categories such as statins and beta blockers.
In terms of pipeline developments, the thrombosis market has witnessed a lot of activity, with promising new drugs such as Sanofi-Aventis’ Multaq (launched in the US in 2009), J&J/Bayer’s Xarelto (launched in 2008), Pfizer/BMS’s apixaban (under registration), Eli Lilly/Daiichi Sankyo’s Effient (approved in 2009) and Boehringer Ingelheim’s Pradaxa (launched in 2008). These oral drugs are expected to widen the thrombosis market significantly, while also extending the prescription period. Additionally, these new generation drugs are set to undermine Lovenox’s (Sanofi-Aventis) monopoly in the thrombosis market.
Key features of this report
Epidemiological analysis and forecast prevalence of the major cardiovascular indications such as hypertension, dyslipidemia and stroke over the period 2009–15.
Forecasts and analysis of the major products in the cardiovascular market over the period 2009-15 spread across the major indications and classes of treatments.
Overview of key events in the global cardiovascular market that have impacted treatment trends and sales potential across the major cardiovascular indications.
Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
Detailed analysis across major classes of cardiovascular treatments including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.
Scope of this report
Quantify patient potential, assess treatment trends and sales patterns across the major cardiovascular disorder indications in the US, Japan and top 5 EU markets.
Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of the major classes such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.
Compare the franchises of top pharmaceutical marketers across major indications, and evaluate how market share of leading companies, such as Pfizer, Sanofi-Aventis, Novartis, Merck, AstraZeneca and BMS will change over the next 5 years.
Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the cardiovascular marketplace.
Gain up-to-date competitive intelligence across the cardiovascular portfolio and understand the major issues affecting key pharmaceutical marketers and product development.
Key Market Issues
Angiotensin receptor blockers may cause increased cancer risk: In June 2010, the Lancet Oncololgy journal published a meta-analysis study which indicated that ARBs (angtiotensin receptor blockers) have an increased cancer risk. The study involved 61,590 patients from five clinical trials and the results demonstrated that ARBs increased the relative risk of new cancer occurrence by 7.2% versus 6% in control groups
Crestor’s patent upheld in the US: AstraZeneca’s blockbuster antidyslipidemic Crestor, the biggest growth driver within cholesterol lowering drugs received a boost after its patent was upheld by a US district court in June 2010, following a four month trial which began in February same year. Crestor is currently the only branded statin in the US market which is witnessing positive growth and this judgement is expected to improve its prospects through the forecast period.
Plavix boxed warning for poor metabolizers: Sanofi-Aventis’/BMS’ Plavix, received a boxed warning to its US label in March 2010, indicating a warning about the diminished effectiveness of the drug in patients with a variant of the CYP2C1P liver enzyme leading to reduced formation of the active metabolite. Sanofi-Aventis conducted a study in 40 subjects, with 10 each in the four metabolizer types and found that the poor metabolizers had notably lower levels of Plavix and anti-platelets. This patient pool termed as poor metabolizers includes approximately 14% of Chinese, 4% of blacks and 2% of caucasians.
Apixaban’s Phase III AVERROES trial halted: In June 2010, BMS halted its Phase III AVERROES trial in vitamin K antagonist intolerant patients with atrial fibrillation. Interim data from the trial revealed that the drug reduced stroke and systemic embolism in comparison with aspirin, in addition to demonstrating sufficient safety prompting the company to take this decision. Apixaban has already been filed in the EU for prevention of VTE in adults who are undergoing elective hip or knee replacement therapies.
Key findings from this report
The global cardiovascular market was valued over $120bn in sales in 2009. The US continued to be the single largest market which was mainly attributed to increasing generic presence and market maturity in several key therapeutic categories. However, Business Insights anticipates the market to decline through 2015 due to the impending patent expiries of several leading drugs.
Antihypertensives remained the largest selling therapeutic sub-category in 2009 led by Novartis’s Diovan. Pfizer’s Norvasc, which was the leading antihypertensive till 2007, has been noting a steady decline and losing market share to Diovan since 2008.
ARBs continued to be the most prescribed antihypertensives in 2009 although their sales are likely to be clipped by the appearance of Cozaar generics in 2010. ACE inhibitors have been declining due to genericization and competition from ARBs such as the Diovan franchise and Blopress.
Antidyslipidemics formed the second largest segment of the cardiovascular market in 2009. This category was dominated by statins with only a small presence of other drug classes.
Key questions answered
What will be the major growth indications and the accompanying growth drivers in the cardiovascular arena over the period 2009–15?
What are the current trends within the major therapy areas such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents across the seven major markets, and Brazil, Russia, India and China (BRIC)?
How have recent launches from companies such as Pfizer, Sanofi-Aventis, Novartis, Merck, AstraZeneca and BMS performed in the market place?
What are the most promising compounds currently in clinical development for major cardiovascular indications, and what is the forecast commercial potential of these products through 2015?
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/
Browse complete The Cardiovascular Market Outlook to 2015: Competitive landscape, global market analysis, key trends and pipeline analysis Report at:
http://www.reportsandreports.com/reports/27443-the-cardiovascular-market-outlook-to-2015-competitive-landscape.html
Browse all Business Insights Market Research Reports at:
http://www.reportsandreports.com/Publishers/business-insights/